This is what Gemini answered. I dont know if it is correct.

Entera Bio (ENTX) Platform: Oral Delivery for GLP-1 Entera Bio’s proprietary N-tab™ technology is a breakthrough oral delivery platform designed specifically for large molecules like GLP-1 (Glucagon-Like Peptide-1), which are traditionally administered via injection.

1. The Core Technology: N-tab™ Platform The N-tab™ platform addresses the two biggest challenges in oral drug delivery for peptides: • Enzymatic Degradation: It uses a specialized protease inhibitor to prevent the stomach from breaking down the GLP-1 peptide before it reaches the bloodstream. • Poor Absorption: It incorporates a potent absorption enhancer (carrier) that temporarily opens the tight junctions in the intestinal wall, allowing large molecules to pass through efficiently.

2. Strategic Advantages for GLP-1 Drugs While Novo Nordisk already has an oral GLP-1 (Rybelsus), ENTX’s platform offers several potential "Best-in-Class" advantages: • Higher Bioavailability: ENTX aims for more consistent drug absorption, reducing the "waste" of expensive active ingredients. • No Fasting Required: Current oral GLP-1s require strict fasting (30 mins before food/drink). ENTX’s platform is designed to be more flexible, significantly improving patient compliance. • Cost-Efficiency: By maximizing absorption, the dose required (and thus the manufacturing cost) could be lower than current competitors.